Investor Presentaiton

Major R&D Milestones (3ADCs) Project ENHERTUⓇ Target Indication [phase, study name] • HER2+, 3L [P3, DESTINY-Breast02] • HER2+, 2L [P3, DESTINY-Breast03] FY2022 H1 • TLR anticipated • Approved (US/EU) BC GC NSCLC • • • HER2 low, Post chemo [P3, DESTINY-Breast04] HER2 low, chemo naïve [P3, DESTINY-Breast06] HER2+, 2L [P2, DESTINY-Gastric02, EU] HER2 mutated, 2L [P2, DESTINY-Lung01] HER2 mutated, 2L [P2, DESTINY-Lung05, CN] . Filing accepted (JP/US/EU) . Filing planned (CN) • Filing accepted (US) • Approval anticipated (US) • Study start planned NSCLC • 2/3L [P3, TROPION-Lung01] H2 HH As of Jul 2022 FY2023 Daiichi-Sankyo • Approval anticipated (JP) • Approval anticipated (US) • Approval anticipated (EU) • Approval anticipated (JP/EU) ⚫TLR anticipated • TLR anticipated Dato-DXd BC • TNBC, 1L, [P3, TROPION-Breast02] Solid tumors HER3-DXd NSCLC Bold: update from FY2021 Q4 • NSCLC, TNBC [P1/2, TROPION-Pan Tumor02, CN] • • • EGFR mutated, 3L [Registrational P2, HERTHENA-Lung01] EGFR mutated, 2L [P3, HERTHENA-Lung02] ⚫ Study started • Study started • Study start planned BC: breast cancer, GC: gastric cancer, NSCLC: non small cell lung cancer, TLR: top line results The timeline indicated is based on the current forecast and subject to change. • TLR anticipated 39

View entire presentation